Trial Profile
A Study to Evaluate the Efficacy and Safety of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2016
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Therapeutic Use
- 18 Jan 2016 New trial record